Loading organizations...

Next generation infectious disease test kits
Lucira Health has raised $30.0M across 3 funding rounds.
Key people at Lucira Health.
Lucira Health was founded in 2013 by Debkishore Mitra (Founder).
Lucira Health has raised $30.0M in total across 3 funding rounds.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.
Lucira Health is a pioneering biotech company specializing in next-generation infectious disease test kits, notably the first FDA-authorized at-home molecular COVID-19 test. Its mission is to empower individuals to take control of their health by providing rapid, accessible, and accurate diagnostic testing from the comfort of home, enabling faster treatment decisions without visiting healthcare facilities. Lucira’s core product is a battery-powered, palm-sized molecular testing device that delivers lab-quality results in 30 minutes or less, initially developed for flu diagnostics and later adapted for COVID-19 and combined COVID-19/flu testing. The company serves consumers, healthcare providers, and public health systems, addressing the critical need for decentralized, user-friendly infectious disease diagnostics. Before its acquisition by Pfizer in 2023, Lucira demonstrated strong growth momentum through regulatory approvals in multiple countries and strategic partnerships, positioning itself as a leader in digital health diagnostics[1][2][3].
Founded in 2013 as Diassess by Dr. Debkishore Mitra, a scientist and current CTO, and entrepreneur John Waldeisen, Lucira Health emerged from a vision to create inexpensive, disposable diagnostics that could transform smartphones into portable health monitoring devices. The company rebranded to Lucira Health in 2019, maintaining its mission to revolutionize infectious disease testing by enabling rapid, multiplexed analysis anywhere. Early development focused on molecular diagnostics for the flu, which laid the groundwork for their breakthrough COVID-19 test. A pivotal moment was securing FDA Emergency Use Authorization (EUA) for the first at-home molecular COVID-19 test during the pandemic, propelling the small firm into the spotlight. Lucira went public in 2021 before being acquired by Pfizer in 2023, marking a significant evolution in its growth and market reach[1][4][6].
Lucira Health rides the wave of digital health and decentralized diagnostics, a trend accelerated by the COVID-19 pandemic’s demand for accessible, rapid testing. The timing was critical as public health systems sought scalable, at-home solutions to reduce transmission and ease healthcare burdens. Market forces favor molecular diagnostics due to their accuracy and growing consumer demand for health autonomy. Lucira’s technology exemplifies the shift from centralized lab testing to personalized, real-time health monitoring, influencing the broader ecosystem by setting new standards for at-home infectious disease detection and fostering innovation in portable molecular diagnostics[1][2][6].
Post-acquisition by Pfizer, Lucira Health’s platform is poised to expand into new infectious disease areas such as respiratory illnesses, sexually transmitted infections, and women’s health, leveraging its proven untethered molecular testing technology. Future trends shaping its journey include the rise of streaming healthcare—integrated test-to-treatment models at home—and increasing consumer demand for digital health empowerment. Lucira’s influence is likely to grow as it helps mainstream molecular diagnostics beyond COVID-19, driving broader adoption of personalized, rapid testing solutions that could redefine infectious disease management globally[2].
This trajectory ties back to Lucira’s founding vision of democratizing infectious disease testing, transforming how individuals engage with their health through innovative, accessible technology.
Key people at Lucira Health.
Lucira Health was founded in 2013 by Debkishore Mitra (Founder).
Lucira Health has raised $30.0M in total across 3 funding rounds.
Lucira Health's investors include John Shen, Atomico, Balderton Capital, CRV, Eclipse Ventures, Lightspeed Venture Partners, SOSV, SQN Venture Partners, Biz Stone, George Godula, Mario Götze, Scott Belsky.
Lucira Health has raised $30.0M across 3 funding rounds. Most recently, it raised $15.0M Series B in August 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2019 | $15.0M Series B | John Shen | Atomico, Balderton Capital, CRV, Eclipse Ventures, Lightspeed Venture Partners, SOSV, SQN Venture Partners, Biz Stone, George Godula, Mario Götze, Scott Belsky, Tim Kendall, Seraph Group |
| Oct 1, 2015 | $13.0M Series A | Ascend Vietnam Ventures, Atomico, Balderton Capital, CRV, Eclipse Ventures, Lightspeed Venture Partners, Primitive Ventures, SOSV, SQN Venture Partners, Biz Stone, George Godula, Mario Götze, Scott Belsky, Tim Kendall | |
| Nov 1, 2014 | $2.0M Seed | Ascend Vietnam Ventures, Primitive Ventures |